Buy Arcus Biosciences
Amount
Latest price
$9.54
(£1.00 = $1.295)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$1.027B
P/E ratio
-3.09
EPS
-$3.141
Beta
1.45
Dividend rate
N/A
Dividend yield
N/A
About
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
CEO
Dr. Terry J. Rosen, Ph.D.
Employees
627
Sector
Health
Company HQ
HAYWARD, United States of America
Website
News
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th.
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago.
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. “Last week, we presented data from nearly 90 ccRCC patients demonstratin.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.